Literature DB >> 24856103

A PEG-Fmoc conjugate as a nanocarrier for paclitaxel.

Peng Zhang1, Yixian Huang1, Hao Liu2, Rebecca T Marquez2, Jianqin Lu1, Wenchen Zhao3, Xiaolan Zhang1, Xiang Gao1, Jiang Li1, Raman Venkataramanan3, Liang Xu2, Song Li4.   

Abstract

We report here that a simple, well-defined, and easy-to-scale up nanocarrier, PEG5000-lysyl-(α-Fmoc-ε-t-Boc-lysine)2 conjugate (PEG-Fmoc), provides high loading capacity, excellent formulation stability and low systemic toxicity for paclitaxel (PTX), a first-line chemotherapeutic agent for various types of cancers. 9-Fluorenylmethoxycarbonyl (Fmoc) was incorporated into the nanocarrier as a functional building block to interact with drug molecules. PEG-Fmoc was synthesized via a three-step synthetic route, and it readily interacted with PTX to form mixed nanomicelles of small particle size (25-30 nm). The PTX loading capacity was about 36%, which stands well among the reported micellar systems. PTX entrapment in this micellar system is achieved largely via an Fmoc/PTX π-π stacking interaction, which was demonstrated by fluorescence quenching studies and (13)C NMR. PTX formulated in PEG-Fmoc micelles demonstrated sustained release kinetics, and in vivo distribution study via near infrared fluorescence imaging demonstrated an effective delivery of Cy5.5-labled PTX to tumor sites. The maximal tolerated dose for PTX/PEG-Fmoc (MTD > 120 mg PTX/kg) is higher than those for most reported PTX formulations, and in vivo therapeutic study exhibited a significantly improved antitumor activity than Taxol, a clinically used formulation of PTX. Our system may hold promise as a simple, safe, and effective delivery system for PTX with a potential for rapid translation into clinical study.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  9-Fluorenylmethoxycarbonyl; Cancer therapy; Drug delivery; Drug–carrier interaction; Micelle; Paclitaxel

Mesh:

Substances:

Year:  2014        PMID: 24856103      PMCID: PMC4102141          DOI: 10.1016/j.biomaterials.2014.04.108

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  30 in total

Review 1.  Long-circulating and target-specific nanoparticles: theory to practice.

Authors:  S M Moghimi; A C Hunter; J C Murray
Journal:  Pharmacol Rev       Date:  2001-06       Impact factor: 25.468

2.  Supramolecular hydrogels respond to ligand-receptor interaction.

Authors:  Yan Zhang; Hongwei Gu; Zhimou Yang; Bing Xu
Journal:  J Am Chem Soc       Date:  2003-11-12       Impact factor: 15.419

Review 3.  Structure and design of polymeric surfactant-based drug delivery systems.

Authors:  V P Torchilin
Journal:  J Control Release       Date:  2001-06-15       Impact factor: 9.776

4.  Hydrotropic polymer micelle system for delivery of paclitaxel.

Authors:  Kang Moo Huh; Sang Cheon Lee; Yong Woo Cho; Jaehwi Lee; Jae Hyun Jeong; Kinam Park
Journal:  J Control Release       Date:  2005-01-03       Impact factor: 9.776

Review 5.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review.

Authors:  H Maeda; J Wu; T Sawa; Y Matsumura; K Hori
Journal:  J Control Release       Date:  2000-03-01       Impact factor: 9.776

Review 6.  Paclitaxel and its formulations.

Authors:  Anil K Singla; Alka Garg; Deepika Aggarwal
Journal:  Int J Pharm       Date:  2002-03-20       Impact factor: 5.875

7.  Folate receptor targeted biodegradable polymeric doxorubicin micelles.

Authors:  Hyuk Sang Yoo; Tae Gwan Park
Journal:  J Control Release       Date:  2004-04-28       Impact factor: 9.776

Review 8.  Micelles from lipid derivatives of water-soluble polymers as delivery systems for poorly soluble drugs.

Authors:  Anatoly N Lukyanov; Vladimir P Torchilin
Journal:  Adv Drug Deliv Rev       Date:  2004-05-07       Impact factor: 15.470

Review 9.  Paclitaxel (taxol)

Authors:  E K Rowinsky; R C Donehower
Journal:  N Engl J Med       Date:  1995-04-13       Impact factor: 91.245

10.  Folate-receptor-targeted delivery of doxorubicin nano-aggregates stabilized by doxorubicin-PEG-folate conjugate.

Authors:  Hyuk Sang Yoo; Tae Gwan Park
Journal:  J Control Release       Date:  2004-11-24       Impact factor: 9.776

View more
  16 in total

1.  A multi-functional polymeric carrier for simultaneous positron emission tomography imaging and combination therapy.

Authors:  Jingjing Sun; Lingyi Sun; Jianchun Li; Jieni Xu; Zhuoya Wan; Zubin Ouyang; Lei Liang; Song Li; Dexing Zeng
Journal:  Acta Biomater       Date:  2018-06-06       Impact factor: 8.947

2.  Effective co-delivery of doxorubicin and dasatinib using a PEG-Fmoc nanocarrier for combination cancer chemotherapy.

Authors:  Peng Zhang; Jiang Li; Mohammed Ghazwani; Wenchen Zhao; Yixian Huang; Xiaolan Zhang; Raman Venkataramanan; Song Li
Journal:  Biomaterials       Date:  2015-07-15       Impact factor: 12.479

3.  The self-assembling camptothecin-tocopherol prodrug: An effective approach for formulating camptothecin.

Authors:  Jianqin Lu; Chuang Liu; Pengcheng Wang; Mohammed Ghazwani; Jieni Xu; Yixian Huang; Xiaochao Ma; Peijun Zhang; Song Li
Journal:  Biomaterials       Date:  2015-05-31       Impact factor: 12.479

4.  A prodrug micellar carrier assembled from polymers with pendant farnesyl thiosalicylic acid moieties for improved delivery of paclitaxel.

Authors:  Jingjing Sun; Yichao Chen; Ke Li; Yixian Huang; Xiaofeng Fu; Xiaolan Zhang; Wenchen Zhao; Yuan Wei; Liang Xu; Peijun Zhang; Raman Venkataramanan; Song Li
Journal:  Acta Biomater       Date:  2016-07-12       Impact factor: 8.947

5.  Multifunctional Mesoporous Polydopamine With Hydrophobic Paclitaxel For Photoacoustic Imaging-Guided Chemo-Photothermal Synergistic Therapy.

Authors:  Liren Zhang; Peng Yang; Ranran Guo; Jiaxin Sun; Ruihong Xie; Wuli Yang
Journal:  Int J Nanomedicine       Date:  2019-11-04

6.  Low density lipoprotein mimic nanoparticles composed of amphipathic hybrid peptides and lipids for tumor-targeted delivery of paclitaxel.

Authors:  Junyi Qian; Ningze Xu; Xu Zhou; Kaihong Shi; Qian Du; Xiaoxing Yin; Ziming Zhao
Journal:  Int J Nanomedicine       Date:  2019-09-11

7.  In vivo synergistic anti-tumor effect of paclitaxel nanoparticles combined with radiotherapy on human cervical carcinoma.

Authors:  YanXin Yu; Shan Xu; Hong You; YinJie Zhang; Bo Yang; XiaoYang Sun; LingLin Yang; Yue Chen; ShaoZhi Fu; JingBo Wu
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

8.  Targeted delivery of anticancer agents via a dual function nanocarrier with an interfacial drug-interactive motif.

Authors:  Xiaolan Zhang; Yixian Huang; Wenchen Zhao; Hao Liu; Rebecca Marquez; Jianqin Lu; Peng Zhang; Yifei Zhang; Jiang Li; Xiang Gao; Raman Venkataramanan; Liang Xu; Song Li
Journal:  Biomacromolecules       Date:  2014-10-28       Impact factor: 6.988

9.  An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy.

Authors:  Yichao Chen; Rui Xia; Yixian Huang; Wenchen Zhao; Jiang Li; Xiaolan Zhang; Pengcheng Wang; Raman Venkataramanan; Jie Fan; Wen Xie; Xiaochao Ma; Binfeng Lu; Song Li
Journal:  Nat Commun       Date:  2016-11-07       Impact factor: 14.919

Review 10.  Tumor-Associated Fibroblast-Targeting Nanoparticles for Enhancing Solid Tumor Therapy: Progress and Challenges.

Authors:  Wenpan Li; Nicholas Little; Jonghan Park; Cole Alexander Foster; Jiawei Chen; Jianqin Lu
Journal:  Mol Pharm       Date:  2021-07-14       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.